Nagao Hideki 4

What Happened

• Hideki Nagao, a director of MediciNova, was granted a derivative equity award for 44,500 shares on 2026-06-23. The filing reports a price of $0.00 per share and a reported value of $0 for the acquisition (listed as an award/derivative).
• This was an equity grant (award of a derivative interest), not an open-market purchase or sale. Such awards are common for compensation and retention; they are acquisitions on paper but do not necessarily reflect an immediate cash purchase of shares.

Key Details

• Transaction date: 2026-06-23; filing date: 2026-06-25 (Form 4 filed within the typical 2-business-day window).
• Reported price: $0.00 per share; total reported value: $0 (derivative award as reported).
• Shares involved: 44,500 (derivative award).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The option vests in four equal installments on 9/30/2026, 12/31/2026, 3/31/2027 and 6/30/2027, subject to continued service with the company.

Context

• This was an option/derivative grant that will vest over time; no exercised shares or sale proceeds are reported now. Until vesting (and any potential exercise), these awards do not represent immediately tradable shares.
• Grants like this are typically part of compensation/retention arrangements and should be viewed as different from open-market purchases or insider sales.